Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-01-24
2006-01-24
Gitomer, Ralph (Department: 1655)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S389200
Reexamination Certificate
active
06989248
ABSTRACT:
This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a methods of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
REFERENCES:
patent: 5877396 (1999-03-01), Ravetch et al.
patent: 5911988 (1999-06-01), Brownell et al.
patent: 5997865 (1999-12-01), Bennett et al.
patent: 6576812 (2003-06-01), Longley
Anderson, D.M., et al. (1990) “Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms” Cell, 63:235-243.
Bradl, M., et al. (1991) “Clonal coar color variation due to a transforming gene expressed in melanocytes of transgenic mice” Proc. Nat. Acad. Sci. USA 88:6447-6451.
Costa, J. J. et al. (1996) “Recombinant human stem cell factor (KIT ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo” J. Exp. Med 183: 2681-2686.
Funasaka, Y., et al. (1992) “C-kit-kinasse induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in respnse to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas” Mol. Biol. Cell, 3:197-209.
Furitsu, T., et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in human mast cell leuemia cell line causing ligand independent activation of c-KIT product J. Clin. Invest., 92:1736-1744.
Grichnik, J. M., et al. (1995) “Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients” J. Am. Acad. Dermol., 33: 577-283.
Hamann, K., et al. (1995) “Expression of stem cell factor in cutaneous mastocytosis” Br. J.Dermatol., 133: 203-208.
Harrist, T.J., et al. (1995) Recombinant human stem cell factor in (SCF) (C-kit ligand promotes melanocytes hyperplasia and activation in vivo Lab. Invest., 72:48A.
Hirobe, T. (1984) “Histochemical survey of the distribution of the epidermal melanoblasts and melanocytes in the mouse during fetal and postnatal periods” Anat. Rec., 208:589-594.
Longley, B. J. et al. (1993) “Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis” N. Engl. J. Med. . 328:1302-1307.
Longley, B. J. et al. (1995) “The mast cell and mast cell disease” J. Am. Acad. Dermatol., 32:545-561.
Longley, B. J., et al. (1996) “Somastic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm” Nature Genetics,12:312-314.
Lu, H. S., et al. (1991) “Amino acid sequence and post-translational modification of stem cell factor isolated from buffalo rat liver cell-conditioned medium” J. Biol. Chem., 266:8102-8107.
Nishikawa, S., et al. (1991) “In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development” EMBO J.10:2111-2118.
Okura, M., et al. (1995) “Effects of monoclonal anti-c-kit antibody (AKC2) on melanocytes in newborn mice” J. Invest. Dermatol., 105:322-328.
Tsai, M., et al. (1991) “The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosol mast cells in vivo: analysis by anatomical distribution, hisochemistry, and protease phenotype” J. Exp. Med., 174:125-131.
Vassar, R., et al. (1989) “Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice” Proc. Natl. Acad. Sci. USA, 86:1563-1567.
Weiss, R. R. et al. (1995) “Human dermal endothelial cells express membrane-associated mast cell growth factor” J. Invest. Dermatol. 104:101-106.
Williams, D.E., et al. (1990) “Identification of a ligand for the c-kit proto-oncogene”Cell, 1990;63:167-174.
Yarden, Y., et al. (1987) “Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand” EMBO J. 6:3341-3351.
Yoshida, H., et al. (1996) “Distinct stages of melanocyte differentiation revealed by analysis of nonuniform pigmentation patterns” Development, 122:1207-1214.
Yohida, H. et al. (1996) “Neural and skin cell- specific expression pattern conferred by Steel factor regulatory sequence in transgenic mice” Development Dynamic, 207:222-232.
Zsebo, K. M., et al. (1990) “Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor” Cell, 63:213-224.
Ando A, Martin TR, Galli SJ. J. Clin. Invest. 1993, 92:1639-49. (Exhibit 1).
Bischoff SC and Dahinden CA. J. Exp. Med. 1992, 175:237-44. (Exhibit 2).
Coleman JW, Holliday MR, Kimber I, Zsebo KM and Galli SJ. J. Immunol. 1993, 150: 556-62. (Exhibit 3).
Columbo M , Horowitz EM, Botana LM, MacGlashan DW Jr., Bochner BS, Gillis S, Zsebo KM, Galli SJ, Lichtenstein LM. J. Immunol. 1992, 149:599-608. (Exhibit 4).
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, et al: Identification of mutations in the coding sequence of the proto-oncogenec-kitin a human mast cell leukemia cell line causing ligand-independent activation ofc-kitproduct.J. Clin Invest92: 1736-1744, 1993. (Exhibit 5).
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al: Gain-of-function mutations of c-kitin human gastrointestinal stromal tumors.Science279: 577-580, 1998. (Exhibit 6).
Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, et al: Constitutively activating mutations of c-kitreceptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.Blood85: 790-798, 1995. (Exhibit 7).
Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, et al: Activating and dominant inactivatingc-KITcatalytic domain mutations in distinct clinical forms of human mastocytosisProc Natl Acad Sci USA96: 1609-1614, 1999. (Exhibit 8).
Longley BJ, Tyrrell L, Lu S, Ma Y, Langley K, et al: Somatic c-KITactivating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.Nature Genet12: 312-314, 1996.(Exhibit 9).
Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ: Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular juxtamembrane region.J Biol Chem274: 13399-13402, 1999b. (Exhibit 10).
Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH: Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.J Invest Dermatol112: 165-170, 1999a. (Exhibit 11).
Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, et al: Identification of a point of mutation in the catalytic domain of the proctooncogenec-kitin peripheral blood mononuclear cells patients who have mastocytosis with an associated hematologic disorder.Proc Natl Acad Sci USA92: 10560-10564, 1995. (Exhibit 12).
Nakajima K, Hirai K, Yamaguchi M, Takaishi T, Ohta K, Morita Y, Ito K. Biochem. Biophys. Res Commun. 1992, 183:1076-83. (Exhibit 13).
Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, et al: Constitutive activation ofc-kitin FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.Blood87: 273-283, 1996 (Exhibit 14).
Wershil BK, Tsai M, Geissler EN, Zsebo KM, Galli SJ. J. Exp. Med. 1992, 175:245-55.(Exhibit 15).
Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, et al: Human proto-oncogenec-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.EMBO J6: 3341-335 1987. (Exhibit 16).
Devinney R, Gold WV: Establishment of two dog mastocyt
Cooper & Dunham LLP
Gitomer Ralph
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
Methods of use of compounds which inhibit the stem cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of use of compounds which inhibit the stem cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of use of compounds which inhibit the stem cell... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3540121